- Trial phase
- Phase 1/2
- Time to market
- Surzetoclax is in Phase 1/2 trials with no regulatory submissions filed. Assuming successful development, potential approval is likely several years away (5+ years), though this is highly uncertain at this early stage.
- Why 2/10
- No hard dated catalyst (PDUFA, pivotal readout, or regulatory decision) is scheduled within the next 12 months. Surzetoclax is an early Phase 1/2 asset at AbbVie, a mega-cap company with dozens of marketed drugs and a massive pipeline, making this single drug a negligible part of the overall equity story.
Surzetoclax has no scheduled PDUFA date, pivotal readout, or regulatory decision within the next 12 months. The next meaningful event would be early efficacy/safety data from the ongoing Phase 1/2 platform study (NCT06953960) or the Phase 1 CLL/SLL study (NCT06291220), but no readout dates have been announced. For ABBV investors, surzetoclax is a pipeline filler, not a stock-moving catalyst.
Price Chart
Executive Summary
Surzetoclax (ABBV-453) is AbbVie's next-generation oral BCL-2 inhibitor in Phase 1/2 development for relapsed/refractory multiple myeloma and CLL/SLL. It is designed to improve upon AbbVie's own marketed BCL-2 inhibitor venetoclax (Venclexta) by offering better selectivity and a reduced risk of tumor lysis syndrome. The drug is still in early-stage clinical trials with no regulatory filings or PDUFA dates on the horizon. For a company the size of AbbVie (roughly $295B market cap with a massive marketed-drug portfolio), surzetoclax is a tiny early-stage pipeline asset and not a meaningful near-term value driver for the stock.
How It Works
Surzetoclax is a next-generation oral BCL-2 inhibitor. BCL-2 is a protein that helps cancer cells survive by blocking the natural cell-death process (apoptosis). By inhibiting BCL-2, surzetoclax restores the ability of cancer cells to die, particularly in blood cancers like multiple myeloma and certain leukemias. It was designed to be more selective and potentially safer than the first-generation BCL-2 inhibitor venetoclax, which AbbVie already markets as Venclexta.
Trial Status
Surzetoclax is in early-stage clinical development. Three active trials are listed on ClinicalTrials.gov: a Phase 1 monotherapy dose-escalation study in relapsed/refractory multiple myeloma (NCT05308654, still in Phase 1 as of September 2026), a Phase 1 study in relapsed/refractory CLL/SLL (NCT06291220), and a Phase 1/2 open-label platform study evaluating surzetoclax alone or in combination with daratumumab and dexamethasone in multiple myeloma (NCT06953960, started December 2025, currently recruiting). Preclinical data and early trial designs have been presented at ASH 2025 and IMS 2026 conferences.
The Two-Sided Case
Upcoming Catalysts
- Early efficacy/safety data readouts from ongoing Phase 1/2 trials (no specific dates announced)
- Potential future data presentations at hematology/oncology conferences (ASH, IMS, EHA)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report